Coherus Biosciences | CHRS - Cash And Equivalent


Coherus Biosciences reported $82.92M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Akebia Therapeutics USD 155.55M 7.1M Jun/2026
ALKERMES USD 511.53M 159.98M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Amarin USD 143.56M 12.5M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
Baxter International USD 2.15B 133M Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Coherus Biosciences USD 82.92M 32.32M Jun/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Fujifilm JPY 170.55B 9.68B Mar/2026
Gilead Sciences USD 7.63B 64M Mar/2026
Ironwood Pharmaceuticals USD 220.47M 5.01M Mar/2026
Merck USD 6.85B 1.52B Jun/2026
Myriad Genetics USD 115.2M 9.2M Jun/2026
Pacira USD 205.88M 61.57M Jun/2026
Perrigo USD 357.2M 174.4M Mar/2026
Pfizer USD 976M 727M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Teva Pharmaceutical Industries USD 3.74B 185M Mar/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026
Xencor USD 44.66M 30.49M Jun/2026
Zoetis USD 1.48B 465M Jun/2026